Cardiovascular Systems’ (CSI) Predator 360° prospective single-centre clinical study has demonstrated beneficial long-term durability of the Predator 360 PAD system in treating peripheral arterial disease (PAD), or blockages in leg arteries.

Predator 360 PAD systems are percutaneous orbital atherectomy systems indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae.

The study enrolled 46 patients, who underwent primary intervention with the Predator 360° orbital technology followed by adjunctive balloon inflations if necessary, as assisted by the physician.

Treatment with Predator 360° showed a low (10.9%) reintervention rate within 12 months, compared to 40 to 74% of dissection rates for balloon angioplasty.

Principal investigator of the study Dr. Prakash Makam said 12-month data shows the Predator 360° is a durable solution, resulting in modified lesion compliance, and its unique orbital mechanism of action with differential sanding safely removes resistant plaque, reducing the need for high-pressure balloon inflation and stenting.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.